Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Jan;32(1):63–67. doi: 10.1128/aac.32.1.63

Comparison of cefazolin, cefamandole, vancomycin, and LY146032 for prophylaxis of experimental Staphylococcus epidermidis endocarditis.

L J Wheat 1, J W Smith 1, J Reynolds 1, A T Bemis 1, T Treger 1, J A Norton 1
PMCID: PMC172099  PMID: 2831815

Abstract

We evaluated antibiotic prophylaxis in the rabbit model of experimental endocarditis with three strains of Staphylococcus epidermidis of differing susceptibility patterns. For the first strain, which was highly susceptible to methicillin and cephalosporins, vegetations grew S. epidermidis for all 15 untreated rabbits compared with 1 of 20 rabbits receiving cefazolin, 3 of 20 receiving cefamandole, none of 20 receiving vancomycin, and none of 20 receiving LY146032. For the second strain, which was methicillin resistant but cephalosporin susceptible, vegetations were positive for 14 of 15 untreated controls, 4 of 20 receiving cefazolin, 5 of 22 receiving cefamandole, none of 20 receiving vancomycin, and none of 20 receiving LY146032. For the third strain, which was methicillin resistant and only intermediately susceptible to cephalosporin antibiotics, vegetation cultures were positive for 15 of 17 untreated controls, 14 of 21 receiving cefazolin, 11 of 20 receiving cefamandole, 5 of 20 receiving vancomycin, and 0 of 22 receiving LY146032. In conclusion, these studies in the endocarditis model indicate that cefazolin and cefamandole have some protective value against certain strains of S. epidermidis. Vancomycin and LY146032, however, were more active than cephalosporins for all three strains included in this analysis. These findings support the need for trials of vancomycin and LY146032 prophylaxis in patients undergoing placement of prosthetic heart valves.

Full text

PDF
63

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Archer G. L. Antimicrobial susceptibility and selection of resistance among Staphylococcus epidermidis isolates recovered from patients with infections of indwelling foreign devices. Antimicrob Agents Chemother. 1978 Sep;14(3):353–359. doi: 10.1128/aac.14.3.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Archer G. L., Vazquez G. J., Johnston J. L. Antibiotic prophylaxis of experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis. J Infect Dis. 1980 Nov;142(5):725–731. doi: 10.1093/infdis/142.5.725. [DOI] [PubMed] [Google Scholar]
  3. Dajee H., Laks H., Miller J., Oren R. Profound hypotension from rapid vancomycin administration during cardiac operation. J Thorac Cardiovasc Surg. 1984 Jan;87(1):145–146. [PubMed] [Google Scholar]
  4. Ein M. E., Smith N. J., Aruffo J. F., Heerema M. S., Bradshaw M. W., Williams T. W., Jr Susceptibility and synergy studies of methicillin-resistant Staphylococcus epidermidis. Antimicrob Agents Chemother. 1979 Nov;16(5):655–659. doi: 10.1128/aac.16.5.655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Eliopoulos G. M., Thauvin C., Gerson B., Moellering R. C., Jr In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic. Antimicrob Agents Chemother. 1985 Mar;27(3):357–362. doi: 10.1128/aac.27.3.357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fass R. J., Helsel V. L. In vitro activity of LY146032 against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother. 1986 Nov;30(5):781–784. doi: 10.1128/aac.30.5.781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hansen B. G. Population analysis of susceptibility to methicillin, vancomycin, and three cephalosporines in two methicillin-resistant strains of Staphylococcus epidermidis. Acta Pathol Microbiol Immunol Scand B. 1983 Aug;91(4):279–284. doi: 10.1111/j.1699-0463.1983.tb00047.x. [DOI] [PubMed] [Google Scholar]
  8. Karchmer A. W., Archer G. L., Dismukes W. E. Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. Ann Intern Med. 1983 Apr;98(4):447–455. doi: 10.7326/0003-4819-98-4-447. [DOI] [PubMed] [Google Scholar]
  9. Lowy F. D., Chang D. S., Lash P. R. Synergy of combinations of vancomycin, gentamicin, and rifampin against methicillin-resistant, coagulase-negative staphylococci. Antimicrob Agents Chemother. 1983 Jun;23(6):932–934. doi: 10.1128/aac.23.6.932. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lowy F. D., Hammer S. M. Staphylococcus epidermidis infections. Ann Intern Med. 1983 Dec;99(6):834–839. doi: 10.7326/0003-4819-99-6-834. [DOI] [PubMed] [Google Scholar]
  11. Lowy F. D., Wexler M. A., Steigbigel N. H. Therapy of methicillin-resistant Staphylococcus epidermidis experimental endocarditis. J Lab Clin Med. 1982 Jul;100(1):94–104. [PubMed] [Google Scholar]
  12. Odio C., Mohs E., Sklar F. H., Nelson J. D., McCracken G. H., Jr Adverse reactions to vancomycin used as prophylaxis for CSF shunt procedures. Am J Dis Child. 1984 Jan;138(1):17–19. doi: 10.1001/archpedi.1984.02140390009004. [DOI] [PubMed] [Google Scholar]
  13. Schwalbe R. S., Stapleton J. T., Gilligan P. H. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med. 1987 Apr 9;316(15):927–931. doi: 10.1056/NEJM198704093161507. [DOI] [PubMed] [Google Scholar]
  14. Siebert W. T., Moreland N., Williams T. W., Jr Synergy of vancomycin plus cefazolin or cephalothin against methicillin-resistance Staphylococcus epidermidis. J Infect Dis. 1979 Apr;139(4):452–457. doi: 10.1093/infdis/139.4.452. [DOI] [PubMed] [Google Scholar]
  15. Vazquez G. J., Archer G. L. Antibiotic therapy of experimental Staphylococcus epidermidis endocarditis. Antimicrob Agents Chemother. 1980 Feb;17(2):280–285. doi: 10.1128/aac.17.2.280. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES